Celgene Corp (CELG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2017 | 12-2016 | 09-2016 | 06-2016 | 03-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 5,273,000 | 6,170,000 | 5,522,600 | 5,063,700 | 4,445,500 |
| Marketable Securities | 3,588,000 | 1,800,000 | 1,346,000 | 1,340,000 | 1,261,800 |
| Receivables | 1,614,000 | 1,621,000 | 1,586,300 | 1,514,900 | 1,420,300 |
| Inventories | 509,000 | 498,000 | 507,900 | 490,400 | 470,600 |
| Other current assets | 633,000 | 779,000 | 612,800 | 760,000 | 787,800 |
| TOTAL | $11,617,000 | $10,868,000 | $9,575,600 | $9,169,000 | $8,386,000 |
| Non-Current Assets | |||||
| PPE Net | 958,000 | 930,000 | 891,300 | 854,000 | 840,000 |
| Intangibles | 15,173,000 | 15,258,000 | 15,364,700 | 15,463,600 | 15,640,000 |
| Other Non-Current Assets | 1,072,000 | 1,030,000 | 922,100 | 1,075,400 | 1,097,900 |
| TOTAL | $17,203,000 | $17,218,000 | $17,178,100 | $17,393,000 | $17,577,900 |
| Total Assets | $28,820,000 | $28,086,000 | $26,753,700 | $26,562,000 | $25,963,900 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 500,000 | 501,000 | 501,000 | N/A | N/A |
| Accounts payable and accrued liabilities | 240,000 | 247,000 | 235,400 | 229,800 | 219,700 |
| Accrued Expenses | 1,808,000 | 2,115,000 | 1,847,100 | 1,695,700 | 1,541,800 |
| TOTAL | $2,629,000 | $2,959,000 | $2,649,400 | $1,987,000 | $1,833,900 |
| Non-Current Liabilities | |||||
| Long Term Debt | 13,784,000 | 13,789,000 | 13,802,500 | 14,312,100 | 14,268,300 |
| Deferred Revenues | 56,000 | 55,000 | 62,100 | 49,000 | 57,800 |
| Other Non-Current Liabilities | 2,215,000 | 2,191,000 | 2,103,900 | 2,167,000 | 2,238,900 |
| TOTAL | $18,547,000 | $18,527,000 | $18,454,000 | $19,026,200 | $19,055,200 |
| Total Liabilities | $21,176,000 | $21,486,000 | $21,103,400 | $21,013,200 | $20,889,100 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 780,824 | 777,967 | 775,204 | 775,115 | 774,602 |
| Common Shares | 10,000 | 10,000 | 9,500 | 9,500 | 9,400 |
| Retained earnings | 11,032,000 | 10,074,000 | 9,644,700 | 9,473,300 | 8,875,100 |
| Other shareholders' equity | 410,000 | 419,000 | 144,900 | 250,900 | 252,000 |
| TOTAL | $7,644,000 | $6,600,000 | $5,650,300 | $5,548,800 | $5,074,800 |
| Total Liabilities And Equity | $28,820,000 | $28,086,000 | $26,753,700 | $26,562,000 | $25,963,900 |